Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gastrointestinal Therapeutics Market Size Forecast: How Big Could The Market Get By 2030?
The gastrointestinal therapeutics market has shown robust growth in recent years. It is anticipated to expand from $42.3 billion in 2025 to $44.72 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. The market’s historical expansion stemmed from various factors, including the constrained availability of biologics and advanced gastrointestinal therapies, a rising occurrence of acid reflux and ulcers, a dependency on hospital and clinic-based treatment, growing public awareness concerning digestive health, and the widespread use of traditional over-the-counter antacids and laxatives.
The gastrointestinal therapeutics market size is projected for substantial expansion over the upcoming years. It will grow to $55.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is propelled by factors such as the development of targeted biologics and immunotherapies, the expansion of ambulatory surgical centers and diagnostic laboratories, increased adoption of oral and intravenous delivery systems, growing online pharmacy penetration, and advancements in probiotics and digestive enzyme formulations. Key trends observed within the forecast period encompass a rising prevalence of gastrointestinal disorders, a greater uptake of biologics and advanced therapies, an increase in over-the-counter therapeutics, an intensified focus on personalized gastrointestinal treatments, and expanding online and retail pharmacy distribution.
Get A Free Sample Report With In-Depth Market Insights:
Gastrointestinal Therapeutics Market Development Factors: What’s Supporting Demand?
The increasing prevalence of inflammatory bowel diseases is projected to stimulate the expansion of the gastrointestinal therapeutics market moving forward. Inflammatory bowel disease (IBD) is a persistent condition characterized by inflammation of the digestive tract, primarily involving Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases can be attributed to genetic susceptibility, which causes an abnormal immune response to gut microbes. Gastrointestinal therapeutics play a crucial role in managing and treating bowel diseases by targeting underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, data from the IBD Registry, a UK-based non-profit organization, indicated that over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Hence, the escalating occurrence of inflammatory bowel diseases is fueling the growth of the gastrointestinal therapeutics market.
Gastrointestinal Therapeutics Market Segmentation And Category Overview
The gastrointestinal therapeutics market covered in this report is segmented –
1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics
2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration
3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users
Subsegments:
1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products
2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics
Gastrointestinal Therapeutics Market Transformation Trends: What Innovations Are Driving Change?
Leading companies within the gastrointestinal therapeutics market are prioritizing the development of innovative treatments, such as sustained-release (SR) fixed-dose combination capsules, to boost patient adherence and enhance the efficacy of therapy. These sustained-release (SR) fixed-dose combination capsules are oral medications engineered to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing the frequency of dosing. For example, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, unveiled rabeprazole + levosulpiride SR capsules for the treatment of gastrointestinal disorders across India. This particular formulation integrates rabeprazole, a proton pump inhibitor that reduces stomach acid, with levosulpiride, a prokinetic agent that improves gut motility. Together, these components deliver effective relief from symptoms like heartburn, acid reflux, bloating, and indigestion. This specific combination is extensively prescribed for managing gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.
Gastrointestinal Therapeutics Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation
View The Full Gastrointestinal Therapeutics Market Report:
Gastrointestinal Therapeutics Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model